In this video, Francisco Vega, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into potential therapeutic targets in various subsets of peripheral T-cell lymphoma (PTCL), including inhibitors of DNMT3A and IDH2, and the potential role of venetoclax and combination strategies in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.